Reata Pharmaceuticals, Inc. (RETA) Issues Earnings Results, Misses Expectations By $0.11 EPS
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) posted its quarterly earnings data on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11), Briefing.com reports. The company had revenue of $12.60 million for the quarter, compared to analyst estimates of $12.54 million. Reata Pharmaceuticals’s quarterly revenue was up .0% on a year-over-year basis.
Shares of Reata Pharmaceuticals (NASDAQ RETA) traded down $2.37 during trading on Tuesday, reaching $25.19. 510,300 shares of the company’s stock traded hands, compared to its average volume of 116,495. Reata Pharmaceuticals has a twelve month low of $18.51 and a twelve month high of $41.60. The company has a debt-to-equity ratio of -0.09, a current ratio of 1.34 and a quick ratio of 1.34.
ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/14/reata-pharmaceuticals-inc-reta-issues-earnings-results-misses-expectations-by-0-11-eps.html.
A number of equities analysts have weighed in on RETA shares. Jefferies Group LLC started coverage on shares of Reata Pharmaceuticals in a research report on Wednesday, August 30th. They set a “buy” rating and a $44.00 target price for the company. Leerink Swann started coverage on shares of Reata Pharmaceuticals in a research report on Wednesday, September 13th. They set an “outperform” rating and a $43.00 target price for the company. ValuEngine lowered shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 11th. Citigroup Inc. restated a “buy” rating and issued a $87.00 price objective (up from $39.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $50.00 price objective (up from $38.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $54.71.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Stock Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.